![]() |
市场调查报告书
商品编码
1780320
显微镜市场规模及预测(2021-2031 年)、全球及区域成长机会分析报告涵盖范围:依技术、最终用户及地理划分Microscope Market Size and Forecast 2021-2031, Global and Regional Growth Opportunity Analysis Report Coverage: By Technology, End User, and Geography |
预计显微镜市场规模将从2024年的26.5亿美元增加到2031年的40.3亿美元。预计2025-2031年期间的复合年增长率为6.20%。推动市场成长的主要因素包括科学研究和医疗保健应用的日益增多,以及研发资金的不断增加。此外,在预测期内,显微镜中人工智慧和远端技术的日益整合有望推动市场发展。然而,高昂的初始成本和维护成本是阻碍市场发展的因素之一。
人工智慧 (AI) 与远端技术的整合正在彻底改变显微镜市场,推动成像、资料分析和可近性方面的进步。人工智慧显微镜系统提高了影像解读的精确度、速度和深度,使研究人员和临床医生能够更有效率地从复杂样本中提取有意义的见解。人工智慧演算法可以自动识别和分类细胞,检测组织样本中的异常情况,并即时量化分子相互作用,从而显着减少人为错误并加速诊断过程。基于数位和云端技术的远端显微镜技术是对人工智慧整合的补充,允许专家远端进行高解析度成像和分析。这种能力在远距医疗领域尤其具有变革性,远距诊断可以为医疗资源匮乏或地理位置偏远的人提供及时且准确的医疗服务。远端显微镜的使用也支持协作研究,使全球各地的多位专家能够同时即时查看和操作显微影像,促进跨机构创新和知识共享。例如,蔡司的人工智慧数位显微镜平台将自动影像分析与基于云端的资料共享相结合,使病理学家能够以更高的精度审查幻灯片。同样,徕卡显微系统公司也开发了人工智慧辅助软体工具,可与其显微镜无缝集成,从而比传统的手动分析更快地检测癌细胞和其他病理特征。此外,全球范围内人工智慧整合显微镜的推出正在增加。例如,2024 年 9 月,MedPrime Technologies 推出了 MICALYS,这是一个创新的人工智慧整合数位显微镜平台,旨在彻底改变印度的数位病理学。它提高了诊断精度,简化了工作流程,并提高了整体生产力。这些系统不仅可以改善诊断结果,还可以优化临床和研究实验室的工作流程效率。因此,预计显微镜中人工智慧和远端技术的日益整合将在未来几年促进市场成长。
显微镜在医学教育和培训中至关重要,它使学生和专业人员能够培养实践技能,并加深对人体解剖学和病理学的理解。教育机构正在投资互动式数位显微镜平台,以实现虚拟显微镜和远距学习。此外,显微镜在兽医学、环境科学和农业研究中也发挥着至关重要的作用,可用于监测动物健康状况、检测环境污染物并提高作物产量。例如,电子显微镜广泛应用于植物病理学,用于研究影响作物的病毒和真菌,从而促进抗病植物品种的培育。因此,研究和医疗保健应用范围的不断扩大,加上显微镜技术的进步,推动了显微镜市场的成长。
此外,政府、私人机构和组织正在向医疗保健、生物技术、奈米技术和材料科学等领域的科学研究和开发投入更多资源。资金的激增使研究机构和大学能够采购最先进的显微镜设备。例如,美国国立卫生研究院 (NIH) 一直在增加预算,到 2025 年将超过 480 亿美元。该预算的很大一部分用于支持严重依赖显微成像技术的研究,从癌症生物学到传染病研究。这些资金的涌入鼓励实验室从传统显微镜升级到更先进的型号,例如共聚焦显微镜、电子显微镜和超解析度显微镜,这些显微镜可以提供更高的精度和更详细的成像能力。
比较公司分析根据产品组合(产品满意度、产品特性和可用性)、近期市场发展(併购、新产品发布和增强、投资和融资、奖励、协议、合作和伙伴关係、认可和扩展)以及地理位置对体外肺模型市场进行评估和分类,以帮助更好地决策和了解竞争格局。该报告深入探讨了全球体外肺模型市场主要供应商近期的重要发展和创新。主要市场参与者包括卡尔蔡司股份公司、布鲁克公司、徕卡显微系统公司、尼康公司、赛默飞世尔科技公司、奥林巴斯公司、ACCU-SCOPE、牛津仪器公司、Euromex Microscopen BV、Coxem 有限公司和日立高科技公司。
根据技术,显微镜市场细分为光学显微镜、电子显微镜、扫描探针显微镜和其他显微镜。光学显微镜在2024年占据了显微镜市场的最大份额,预计在2025年至2031年期间将实现显着的复合年增长率。
就最终用户而言,显微镜市场细分为学术机构和研究机构、製药和生物製药公司、诊断中心等。製药和生物製药公司在2024年占据了显微镜市场的最大份额,预计在2025-2031年期间将实现显着的复合年增长率。大学、学院和专门的研究中心广泛使用显微镜进行生物学、化学、材料科学、奈米技术等领域的教学、基础研究和实验研究。持续的资金和资助促进了科学知识的累积和创新。学术环境中的显微镜种类繁多,从教室使用的基本光学模型到尖端研究实验室使用的复杂电子显微镜和扫描探针显微镜。光学显微镜仍然是最常用的教学工具,使学生能够探索细胞结构、微生物和组织样本。例如,数位光学显微镜越来越多地被整合到课程中,以增强互动式学习体验。同时,研究机构经常投资于透射电子显微镜 (TEM)、扫描电子显微镜 (SEM)、原子力显微镜 (AFM) 和共聚焦显微镜等高端技术,以便在微观和奈米尺度上进行详细的结构、化学和物理分析。此外,政府和私人组织持续拨出大量预算来支援科学基础设施,推动先进显微镜系统的升级和采购。例如,美国国立卫生研究院 (NIH) 和欧洲研究理事会 (ERC) 等机构积极资助显微镜相关项目,为获取最先进设备提供便利。
体外肺模型市场的公司采用各种有机和无机成长策略。有机成长策略主要包括产品发布和产品批准。市场上常见的无机成长策略包括收购、合作和伙伴关係。这些成长策略使市场参与者能够拓展业务,增强地域影响力,并促进整体市场成长。此外,收购和伙伴关係等策略有助于巩固客户群并扩展产品组合。以下列出了体外肺模型市场主要参与者的一些重要进展。
2024 年 10 月,蔡司推出了新款 ZEISS Crossbeam 550 Samplefab,这是一款聚焦离子束扫描电子显微镜 (FIB-SEM),专为全自动製备透射电子显微镜 (TEM) 样品而优化。
2024年6月,徕卡显微系统公司推出了神经外科手术的ARveo 8数位视觉化显微镜的升级版。 ARveo 8透过应用3D视图和扩增实境萤光技术,增强了手术视觉化效果。
The microscope market size is projected to reach US$ 4.03 billion by 2031 from US$ 2.65 billion in 2024. The market is estimated to register a CAGR of 6.20% during 2025-2031. Major factors driving the market growth include an increasing applications of research and healthcare, and the growing funding in research and development. Further, increasing integration of AI and remote technologies in the microscope is likely to boost the market during the forecast period. However, high initial and maintenance costs are among the market deterrents.
The integration of Artificial Intelligence (AI) and remote technologies is revolutionizing the microscope market leading to advancements in imaging, data analysis, and accessibility. AI-powered microscopy systems enhance the precision, speed, and depth of image interpretation, enabling researchers and clinicians to extract meaningful insights from complex samples with greater efficiency. AI algorithms can automatically identify and classify cells, detect abnormalities in tissue samples, and quantify molecular interactions in real time, which significantly reduces human error and accelerates diagnostic processes. Remote microscopy, enabled by digital and cloud technologies, complements AI integration by allowing specialists to conduct high-resolution imaging and analysis remotely. This capability is particularly transformative in telemedicine, where remote diagnostics can provide timely and accurate healthcare services to underserved or geographically isolated populations. The use of remote microscopy also supports collaborative research by enabling multiple experts across the globe to simultaneously view and manipulate microscopic images in real time, fostering cross-institutional innovation and knowledge sharing. For instance, Zeiss's AI-driven digital microscopy platform combines automated image analysis with cloud-based data sharing, allowing pathologists to review slides with enhanced accuracy. Similarly, Leica Microsystems has developed AI-assisted software tools that integrate seamlessly with their microscopes to detect cancer cells and other pathological features more rapidly than traditional manual analysis. Moreover, the launch of AI-integrated microscopes is increasing across the world. For instance, in September 2024, MedPrime Technologies launched MICALYS, which is an innovative AI-integrated digital microscopy platform that is set to revolutionize digital pathology in India. It elevates diagnostic precision, streamlines workflows, and boosts overall productivity. These systems not only improve diagnostic outcomes but also optimize workflow efficiencies in clinical and research laboratories. Therefore, increasing integration of AI and remote technologies in the microscope is expected to contribute the market growth in the coming years.
Microscopy is critical in medical education and training, enabling students and professionals to develop practical skills and a deeper understanding of human anatomy and pathology. Educational institutions are investing in interactive and digital microscopy platforms that allow virtual microscopy and remote learning. Moreover, microscopes are crucial in veterinary medicine, environmental science, and agricultural research to monitor animal health, detect environmental contaminants, and improve crop yields. For instance, electron microscopy is widely used in plant pathology to study viruses and fungi affecting crops, facilitating the development of disease-resistant plant varieties. Therefore, the expanding scope of research and healthcare applications, coupled with technological advancements in microscopy, drives the growth of the microscope market.
Moreover, governments, private institutions, and organizations are allocating more resources toward scientific research and development in healthcare, biotechnology, nanotechnology, and materials science, among others. This surge in funding enables research institutions and universities to procure state-of-the-art microscopy equipment. For instance, the National Institutes of Health (NIH) in the US has consistently increased its budget, reaching over US$ 48 billion in 2025. A significant portion of this budget supports research that relies heavily on microscopic imaging technologies, from cancer biology to infectious disease studies. This influx of funds encourages laboratories to upgrade from conventional microscopes to advanced models such as confocal, electron, and super-resolution microscopes that offer higher precision and more detailed imaging capabilities
The comparative company analysis evaluates and categorizes the in vitro lung models market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global in vitro lung models market. The key market players are CARL ZEISS AG; Bruker Corporation; Leica Microsystems; Nikon Corporation; Thermo Fischer Scientific Inc.; Olympus Corporation; ACCU-SCOPE; Oxford Instruments Plc; Euromex Microscopen BV; Coxem Co.,Ltd; and Hitachi High-Tech Corp.
Based on technology, the microscope market is segmented into optical microscope, electron microscope, scanning probe microscope, and others. The optical microscope segment held the largest share of the microscope market in 2024, and it is expected to register a significant CAGR during 2025-2031.
In terms of end user, the microscope market is segmented into academics and research institutes, pharmaceuticals and biopharmaceutical companies, diagnostic centers, and others. The pharmaceuticals and biopharmaceutical companies segment held the largest share of the microscope market in 2024, and it is expected to register a significant CAGR during 2025-2031. Universities, colleges, and dedicated research centers utilize microscopes extensively for education, fundamental research, and experimental studies in biology, chemistry, materials science, nanotechnology, and others. Continuous funding and grants enhance scientific knowledge and innovations. Microscopes in academic settings range from basic optical models used in classrooms to sophisticated electron and scanning probe microscopes employed in cutting-edge research labs. Optical microscopes remain the most common tool for teaching purposes, enabling students to explore cell structures, microorganisms, and tissue samples. For instance, digital optical microscopes are increasingly integrated into curricula to enhance interactive learning experiences. Meanwhile, research institutes often invest in high-end technologies such as transmission electron microscopes (TEM), scanning electron microscopes (SEM), atomic force microscopes (AFM), and confocal microscopes to conduct detailed structural, chemical, and physical analyses at the micro and nanoscale. Additionally, governments and private organizations continue to allocate significant budgets to support scientific infrastructure, driving upgrades and purchases of advanced microscopy systems. For example, initiatives such as the US National Institutes of Health (NIH) and the European Research Council (ERC) actively fund microscopy-related projects, facilitating access to state-of-the-art equipment.
Various organic and inorganic strategies are adopted by companies operating in the in vitro lung models market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the in vitro lung models market are listed below.
In October 2024, ZEISS launched new ZEISS Crossbeam 550 Samplefab, a focused ion beam scanning electron microscope (FIB-SEM) optimized for fully automated preparation of transmission electron microscopy (TEM) samples.
In June 2024, Leica Microsystems introduced an evolved version of its ARveo 8 digital visualization microscope for neurosurgery. The ARveo 8 enhances surgical visualization by applying a 3D view and augmented reality fluorescence.